Avadel Pharmaceuticals plc (AVDL) Stock Ticker
AVDL right now
Market factors today
Unlock the full AVDL picture
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
AVDL stock facts
| Ticker symbol | AVDL |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market cap | $2.1B |
| CEO | Gregory J. Divis Jr. |
| Employees | 188 |
| Headquarters | Dublin, IE |
| IPO date | 1996-06-07 |
| Website | investor.alkermes.com/news-releases/news-release-details/alkermes-plc-completes-acquisition-avadel-pharmaceuticals-plc |
What you can see for AVDL on Tickr
Live AVDL price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the AVDL report.
Rankings
FAQ
What is the ticker symbol for Avadel Pharmaceuticals plc?
The ticker symbol for Avadel Pharmaceuticals plc is AVDL, listed on the NASDAQ Global Market.
What is AVDL?
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with…